Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

Current GLP-1 drugs for diabetes and obesity management often require frequent injections due to their short half-life. In just two weeks, IPA's LENS ai generated, developed and optimized novel ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

We recently compiled a list of the 10 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to ...